rhPTH(1-84) for hypoparathyroidism: a randomized study of patient-reported outcomes
Open Access
- 25 July 2025
- journal article
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 193 (2) , 310-319
Abstract
Objective: To assess the impact of recombinant human parathyroid hormone (1-84) [rhPTH(1-84)] compared with placebo, in combination with conventional therapy with vitamin D and/or calcium supplements, on health-related quality of life (HRQoL) in patients with symptomatic chronic hypoparathyroidism (cHypoPT). Design: Randomized, double-blind, placebo-controlled, phase 3b-4 study (ClinicalTrials.gov ID: NCT03324880). Methods: Eligible patients with symptomatic cHypoPT were randomized to receive subcutaneous rhPTH(1-84) 25-100 µg/day or placebo. The primary endpoint was the change from baseline to week 26 in Hypoparathyroidism Symptom Diary (HypoPT-SD) symptom subscale score. Key secondary endpoints were changes from baseline to week 26 in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue and in 36-item Short Form Health Survey physical component summary (SF-36v2 PCS). Results: In total, 93 patients were randomized to receive treatment: 45 received rhPTH(1-84) and 48 received placebo. Change from baseline to week 26 in HypoPT-SD symptom subscale score was significantly greater (improved) in the rhPTH(1-84) group than in the placebo group (difference in least-squares mean changes, −0.53; 95% confidence interval, −0.90 to −0.15, P = .003). Key secondary endpoints, changes between baseline and week 26 in the FACIT-Fatigue and SF-36v2 PCS scores were also significantly greater (improved) in the rhPTH(1-84) group than in the placebo group. The safety profile of rhPTH(1-84) was consistent with previous findings, and no new safety signals were identified. Conclusions: rhPTH(1-84) alongside conventional therapy improved symptom burden (as measured by the HypoPT-SD) and HRQoL to a greater extent than conventional therapy alone in patients with symptomatic cHypoPT.Keywords
Funding Information
- Takeda Development Center Americas, Inc.
This publication has 23 references indexed in Scilit:
- The Influence of Conventional Treatment on Symptoms and Complaints in Patients With Chronic Postsurgical HypoparathyroidismJBMR Plus, 2021
- Evaluation and Management of Hypoparathyroidism Summary Statement and Guidelines from the Second International WorkshopJournal of Bone and Mineral Research, 2020
- The effects of patient and disease-related factors on the quality of life in patients with hypoparathyroidismArchives of Osteoporosis, 2020
- Burden of illness in not adequately controlled chronic hypoparathyroidism: Findings from a 13‐country patient and caregiver surveyClinical Endocrinology, 2019
- Development of a Patient-Reported Outcome Measure for Chronic HypoparathyroidismAdvances in Therapy, 2019
- Effects of PTH(1–84) therapy on muscle function and quality of life in hypoparathyroidism: results from a randomized controlled trialOsteoporosis International, 2014
- Parathyroidectomy, Elevated Depression Scores, and Suicidal Ideation in Patients With Primary HyperparathyroidismJAMA Surgery, 2013
- HypoparathyroidismNew England Journal of Medicine, 2008
- SF-36 Health Survey UpdateSpine, 2000
- The MOS 36-ltem Short-Form Health Survey (SF-36)Medical Care, 1992